HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin Plc  FORM 8.5

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
116
HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin Plc

 FORM 8.5 EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Name of exempt principal trader: HSBC BANK PLC
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree   Lonmin Plc
(c) Name of the party to the offer with which exempt principal trader is connected:   Sibanye Gold Ltd
(d) Date dealing undertaken:   21 May 2018
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? If it is a cash offer or possible cash offer, state "N/A"   Yes - Sibanye Gold Ltd

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales   Total number of securities Highest price per unit paid/received (GBP) Lowest price per unit paid/received (GBP)
Ordinary Shares Purchase 54,023   49.000 p   47.360 p
Ordinary Shares    Sale 54,023   49.000 p   47.360 p

(b)        Derivatives transactions (other than options)

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (GBP)
         

(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii)        Exercising

Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
         

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
         

3.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
    None  

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None
Date of disclosure: 22 May 2018
Contact name: Sukant Roy
Telephone number: 0207 088 2000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading

Top 5 Most Recently Viewed Articles

BioXcel Therapeutics Faces Challenges Amidst 52-Week Low

Updated Category News Views 85

BioXcel Therapeutics: Facing the Heat BioXcel Therapeutics Inc. (BTAI) is in the doghouse—its stock just hit a jaw-dropping 52-week low of $0.53. That's an eye-watering drop of over 80% in the last year. Investors are glued to their screens, weighing whether to grab some shares at rock-bottom prices or steer clear as BioXcel grapples with mounting obstacles. This sharp...

Continue Reading
Guidehouse Welcomes Ron White as New Chief Information Officer

Updated Category News Views 315

Guidehouse Appoints Ron White as Chief Information Officer Advancing the firm's AI-led strategy with visionary leadership to drive business transformation and scalable innovation MCLEAN, Va. – Guidehouse, a global AI-led professional services firm, has recently appointed Ron White as its Chief Information Officer (CIO). With over 35 years of expertise in enterprise...

Continue Reading
Natural Ingredients Driving Growth in Cosmetics Market

Updated Category News Views 186

Market Growth Driven by Consumer Demand Recent studies indicate that the chemicals market for cosmetics and toiletries is experiencing significant growth. The market is set to increase from $27.7 billion to an impressive $35 billion by the end of 2029. This momentum speaks volumes about the trends affecting consumer preferences and the investment patterns of leading...

Continue Reading
Securities Investigation Alert for Semler Scientific Investors

Updated Category News Views 118

Understanding the Semler Scientific Investigation The Rosen Law Firm is actively investigating potential securities claims for investors of Semler Scientific, Inc. (NASDAQ: SMLR). This initiative addresses concerns regarding the possibility that the company may have provided significantly misleading information about its business practices to the public. Why You Should Be...

Continue Reading
Exciting Updates from Bitget Wallet: Join Fomo Thursdays

Updated Category News Views 390

Bitget Wallet Introduces Fomo Thursdays Events Bitget Wallet, a prominent non-custodial crypto wallet, is thrilled to announce the launch of its fourth Fomo Thursdays event, brought to life in collaboration with Velo Protocol. This event focuses on broadening participation in the crypto space, featuring a staggering prize pool of 3.47 million VELO tokens and 50,000 slots...

Continue Reading